An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom-Reference-Cited by-同舟云学术

An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

Published:2008-09 Issue:5 Volume:11 Page:791-799
ISSN:1098-3015
Container-title:Value in Health
language:en
Short-container-title:Value in Health

Author:

Brown Ben,Diamantopoulos Alexander,Bernier Jacques,Schöffski Patrick,Hieke Klaus,Mantovani Lorenzo,Launois Robert,Griebsch Ingolf,Robinson Paul

Publisher

Elsevier BV

Subject

Public Health, Environmental and Occupational Health,Health Policy

Reference24 articles.

1. Current clinical outcomes demand new treatment options for SCCHN;Lefebvre;Ann Oncol,2005

2. Estimates of the worldwide incidence of 25 major cancers in 1990;Parkin;Int J Cancer,1999

3. Update on chemoradiotherapy for head and neck cancer;Argiris;Curr Opin Oncol,2002

4. State-of-the-art management of locally advanced head and neck cancer;Seiwert;Br J Cancer,2005

5. Chemoradiation for upper aerodigestive tract cancer: balancing evidence from clinical trials with individual patient recommendations;Harari;Curr Probl Cancer,2004

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost–effectiveness of concurrent radiation with cetuximab or chemotherapy in older patients with oropharyngeal cancer;Journal of Comparative Effectiveness Research;2022-06

2. Obinutuzumab Plus Chemotherapy Compared with Rituximab Plus Chemotherapy in Previously Untreated Italian Patients with Advanced Follicular Lymphoma at Intermediate–High Risk: A Cost-Effectiveness Analysis;ClinicoEconomics and Outcomes Research;2021-07

3. Direct costs associated with the management of mucositis: A systematic review;Oral Oncology;2021-07

4. Cost-utility analysis of stereotactic body radiotherapy plus cetuximab in previously irradiated recurrent squamous cell carcinoma of the head and neck;Expert Review of Pharmacoeconomics & Outcomes Research;2021-03-17

5. Preliminary Cost-Effectiveness and Cost-Utility Analysis of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma in Italy;ClinicoEconomics and Outcomes Research;2021-02